<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730962</url>
  </required_header>
  <id_info>
    <org_study_id>GI-2015-22791</org_study_id>
    <nct_id>NCT02730962</nct_id>
  </id_info>
  <brief_title>Interventional Bioremediation of Microbiota in Metabolic Syndrome</brief_title>
  <official_title>Interventional Bioremediation of Microbiota in Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether changing the microbial composition in the&#xD;
      colon can improve metabolism of sugar in people who are on the verge of developing diabetes&#xD;
      (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT)&#xD;
      using material from lean donors, as well as a series of tests prior to and after the&#xD;
      transplant. The investigators will examine any changes in fecal bacterial composition&#xD;
      associated with FMT and determine if any observed changes have an influence on blood sugar&#xD;
      metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Delays in IND approval caused a lack of funding to conduct the trial.&#xD;
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>10 weeks</time_frame>
    <description>Insulin sensitivity measured by standard euglycemic insulin clamp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome Composition</measure>
    <time_frame>7 days</time_frame>
    <description>Outcome is reported as the Shannon alpha diversity index (unitless measure) at baseline and 7 days post FMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fecal Bacterial Composition Associated With FMT Overall Antibiotic and Placebo Conditioning Groups) by Laboratory Analysis.</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Microbiome composition was assessed post FMT using fecal DNA extraction and sequences. Outcome is reported as the change in relative abundance of the family Ruminococcaceae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Rates</measure>
    <time_frame>10 weeks</time_frame>
    <description>Outcome is reported as a patient self report of adverse events over 10 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pre-Diabetes</condition>
  <arm_group>
    <arm_group_label>Antibiotics prior to FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo prior to FMT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 3 times a day for 7 days</description>
    <arm_group_label>Antibiotics prior to FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic</description>
    <arm_group_label>Placebo prior to FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neomycin</intervention_name>
    <description>Neomycin 3 times a day for 1 day</description>
    <arm_group_label>Antibiotics prior to FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>Clindamycin 3 times a day for 5 days</description>
    <arm_group_label>Antibiotics prior to FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>FMT conducted via colonoscopy</description>
    <arm_group_label>Antibiotics prior to FMT</arm_group_label>
    <arm_group_label>Placebo prior to FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide informed consent&#xD;
&#xD;
          2. Ambulatory and community dwelling&#xD;
&#xD;
          3. Age 18 - 70 years of age&#xD;
&#xD;
          4. Able and willing to comply with the study schedule and procedures&#xD;
&#xD;
          5. Pre-diabetic with fasting blood glucose &gt; 100 mg/dL and/or blood glucose 140-200 mg/dL&#xD;
             2-hours after ingestion of 75 gm glucose and/or Hemoglobin A1c &gt; 5.7-6.5 percent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious, concomitant illness that, in the opinion of the Investigator, would interfere&#xD;
             with evaluation of safety or efficacy, or put the subject at risk of harm from study&#xD;
             participation.&#xD;
&#xD;
          2. Known inflammatory bowel disease (Crohn's disease, ulcerative colitis, lymphocytic&#xD;
             colitis).&#xD;
&#xD;
          3. Current abnormal liver tests that may be attributed to a cause other than&#xD;
             non-alcoholic liver disease. Note: These exclusionary conditions may include viral&#xD;
             hepatitis, alcoholic liver disease, hemochromatosis, Wilson's disease,&#xD;
             medication-induced liver test abnormalities, celiac disease.&#xD;
&#xD;
          4. Renal insufficiency, defined as creatinine â‰¤ 1.25 mg/dL&#xD;
&#xD;
          5. Significant alcohol use, defined as &gt; 20 g/day in females and &gt; 30 g/day in males for&#xD;
             a period of 3 months within one year prior to screening.&#xD;
&#xD;
          6. Underlying chronic gastrointestinal disease that can cause diarrhea, including short&#xD;
             bowel syndrome, diarrhea-predominant irritable bowel syndrome, malabsorption, celiac&#xD;
             disease.&#xD;
&#xD;
          7. History of partial or complete colectomy.&#xD;
&#xD;
          8. History of malabsorptive bariatric surgery.&#xD;
&#xD;
          9. Use of insulin or hypoglycemic medications.&#xD;
&#xD;
         10. History of anaphylactic food allergies, e.g., peanuts, seafood.&#xD;
&#xD;
         11. Food intolerances and allergies, including gluten sensitivity, lactose intolerance,&#xD;
             and intolerance of high fiber dietary content.&#xD;
&#xD;
         12. Symptomatic problems associated with intestinal gas and bloating.&#xD;
&#xD;
         13. Irritable bowel syndrome, including diarrhea-dominant, constipation-dominant, and&#xD;
             mixed.&#xD;
&#xD;
         14. Functional GI disorder.&#xD;
&#xD;
         15. Unable to tolerate a colonoscopy.&#xD;
&#xD;
         16. Presence of an indwelling intravenous line.&#xD;
&#xD;
         17. Infection requiring antibiotics other than the conditioning antibiotics during the&#xD;
             study period.&#xD;
&#xD;
         18. Inability to take vancomycin, neomycin, and clindamycin antibiotics prior to FMT due&#xD;
             to known hypersensitivity or intolerance.&#xD;
&#xD;
         19. Major genetic immune dysfunction (e.g., common variable immune deficiency).&#xD;
&#xD;
         20. Acquired immune deficiencies due to infections such as HIV.&#xD;
&#xD;
         21. Immunosuppressive medications including one of the following: systemic&#xD;
             corticosteroids, calcineurin inhibitors, thiopurines, methotrexate, biologics (e.g.,&#xD;
             anti-tumor necrosis factor drugs), cancer chemotherapy.&#xD;
&#xD;
         22. Planned use of oral probiotics while on study.&#xD;
&#xD;
         23. Planned or ongoing chemotherapy for malignancy.&#xD;
&#xD;
         24. Planned antibiotic therapy within the period of the study, e.g., perioperative&#xD;
             antibiotics.&#xD;
&#xD;
         25. Pregnant or lactating. Female participants of child-bearing age and their partners&#xD;
             will be counseled on contraceptive measures to prevent pregnancy during the study&#xD;
             period.&#xD;
&#xD;
         26. History of drug or alcohol abuse in the past 2 years.&#xD;
&#xD;
         27. Currently participating in another clinical study.&#xD;
&#xD;
         28. Legally incompetent and unable to understand the study's purpose, significance and&#xD;
             consequences, and to make decisions accordingly.&#xD;
&#xD;
         29. Presence of metal implants, such as surgical clips or pacemakers, which will preclude&#xD;
             performance of MRI tests.&#xD;
&#xD;
         30. Inability to undergo MRI testing for any reason, e.g., claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Khoruts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <results_first_submitted>June 28, 2019</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Neomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02730962/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antibiotics Prior to FMT</title>
          <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
        </group>
        <group group_id="P2">
          <title>Placebo Prior to FMT</title>
          <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antibiotics Prior to FMT</title>
          <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
        </group>
        <group group_id="B2">
          <title>Placebo Prior to FMT</title>
          <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="9.63"/>
                    <measurement group_id="B2" value="46.6" spread="7.95"/>
                    <measurement group_id="B3" value="44.9" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>Insulin sensitivity measured by standard euglycemic insulin clamp.</description>
        <time_frame>10 weeks</time_frame>
        <population>Due to errors in formulation of the euglycemic insulin clamp solutions, insulin sensitivity data is not able to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Antibiotics Prior to FMT</title>
            <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Prior to FMT</title>
            <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Insulin sensitivity measured by standard euglycemic insulin clamp.</description>
          <population>Due to errors in formulation of the euglycemic insulin clamp solutions, insulin sensitivity data is not able to be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiome Composition</title>
        <description>Outcome is reported as the Shannon alpha diversity index (unitless measure) at baseline and 7 days post FMT.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotics Prior to FMT</title>
            <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Prior to FMT</title>
            <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiome Composition</title>
          <description>Outcome is reported as the Shannon alpha diversity index (unitless measure) at baseline and 7 days post FMT.</description>
          <units>unitless measure</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.5"/>
                    <measurement group_id="O2" value="3.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days post FMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.5"/>
                    <measurement group_id="O2" value="1.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fecal Bacterial Composition Associated With FMT Overall Antibiotic and Placebo Conditioning Groups) by Laboratory Analysis.</title>
        <description>Microbiome composition was assessed post FMT using fecal DNA extraction and sequences. Outcome is reported as the change in relative abundance of the family Ruminococcaceae.</description>
        <time_frame>Baseline and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotics Prior to FMT</title>
            <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Prior to FMT</title>
            <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fecal Bacterial Composition Associated With FMT Overall Antibiotic and Placebo Conditioning Groups) by Laboratory Analysis.</title>
          <description>Microbiome composition was assessed post FMT using fecal DNA extraction and sequences. Outcome is reported as the change in relative abundance of the family Ruminococcaceae.</description>
          <units>percent relative abundance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="2"/>
                    <measurement group_id="O2" value="17" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Rates</title>
        <description>Outcome is reported as a patient self report of adverse events over 10 weeks.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotics Prior to FMT</title>
            <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Prior to FMT</title>
            <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Rates</title>
          <description>Outcome is reported as a patient self report of adverse events over 10 weeks.</description>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at each study visit during study participation, which was approximately 3-4 months, and collected again at a 6 month follow up visit after study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Antibiotics Prior to FMT</title>
          <description>One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.&#xD;
Vancomycin: Vancomycin 3 times a day for 7 days&#xD;
Neomycin: Neomycin 3 times a day for 1 day&#xD;
Clindamycin: Clindamycin 3 times a day for 5 days&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
        </group>
        <group group_id="E2">
          <title>Placebo Prior to FMT</title>
          <description>One week prior to FMT, a course of three sugar pills identical to each antibiotic.&#xD;
Placebo: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic&#xD;
Fecal Microbiota Transplantation: FMT conducted via colonoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contact Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexander Khoruts</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-2101</phone>
      <email>khoru001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

